Post-transplant lymphoproliferative disorder · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
R, then CHOP Variant #01 | — | R 104 658 | 56d | — | — | ~4 | ~R 107 776 indirect | — |
R-CP Variant #01 | — | R 78 421 | 21d | — | — | ~6 | ~R 159 668 indirect | — |
ACVBP, dose-adjusted Variant #01 Partial | — | R 779 | 14d | — | — | ~6 | ~R 4 674 indirect | — |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~20.3 mo | — | ~1 | — | 20 |
Reduction of immunosuppression Partial | — | — | — | — | — | — | — | — |
5 of 5 regimens shown